Your browser doesn't support javascript.
loading
The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
Nesbitt, Heather; Worthington, Jenny; Errington, Rachel J; Patterson, Laurence H; Smith, Paul J; McKeown, Stephanie R; McKenna, Declan J.
Afiliación
  • Nesbitt H; Biomedical Sciences, Research Institute, University of Ulster, Cromore Road, Coleraine, Northern Ireland, United Kingdom.
  • Worthington J; Axis Bioservices Ltd, Coleraine, Northern Ireland, United Kingdom.
  • Errington RJ; School of Medicine, Cardiff University, Heath Park, Cardiff, United Kingdom.
  • Patterson LH; BioStatus Ltd, Shepshed, Leicestershire, United Kingdom.
  • Smith PJ; OncoTherics Ltd, Shepshed, Leicestershire, United Kingdom.
  • McKeown SR; OncoTherics Ltd, Shepshed, Leicestershire, United Kingdom.
  • McKenna DJ; Biomedical Sciences, Research Institute, University of Ulster, Cromore Road, Coleraine, Northern Ireland, United Kingdom.
Prostate ; 77(15): 1539-1547, 2017 Nov.
Article en En | MEDLINE | ID: mdl-28944496
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Profármacos / Antraquinonas / Etilenodiaminas / Neoplasias de la Próstata Resistentes a la Castración Límite: Animals / Humans / Male Idioma: En Revista: Prostate Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Profármacos / Antraquinonas / Etilenodiaminas / Neoplasias de la Próstata Resistentes a la Castración Límite: Animals / Humans / Male Idioma: En Revista: Prostate Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido